Invasive pneumococcal disease in Spain 2023

Authors

DOI:

https://doi.org/10.4321/s2173-92772024000200003

Keywords:

Invasive pneumococcal disease, Pneumococcal vaccines, Spain, 2023, Epidemiological analysis, RENAVE.

Abstract

Introduction: Epidemiological analysis of invasive pneumococcal disease (IPD) in Spain during 2023 and its comparison with previous years (2015-2022).

Method: Descriptive epidemiological analysis of cases of IPD reported to the National Epidemiological Surveillance Network (RENAVE). The variables analysed were: sex, age, date of symptom onset, reporting region, death, clinical manifestation and serotype.

Results: In 2023, 4,814 cases of IPD were reported in Spain, with an overall cumulative incidence rate per 100,000 inhabitants (IR) of 9.91 (12.16 in men and 7.74 in women). Incidence was highest in the <1-year group (IR of 29.97), followed by those ≥ 65 years (IR of 23.35) and by the 1-4-year group (IR of 23.32). In the <1 year and 1 to 4-year groups, 39.7% and 33.3%, respectively, were caused by serotypes included in PCV13. In the age group ≥65 years, 70.5% of IPDs were caused by a serotype included in PPV23. Vaccine serotypes 8 and 3 caused 41% of the IPDs in which the serotype was reported.

Conclusions: AI increased in all age groups, reaching prepandemic IR. It is necessary to continue improving the quality of the information reported to RENAVE.

Downloads

Download data is not yet available.

References

Orden SSI/445/2015, de 9 de marzo, por la que se modifican los anexos I, II y III del Real Decreto 2210/1995, de 28 de diciembre, por el que se crea la Red Nacional de Vigilancia Epidemiológica, relativos a la lista de enfermedades de declaración obligatoria, modalidades de declaración y enfermedades endémicas de ámbito regional. «BOE» núm. 65, de 17 de marzo de 2015, páginas 24012 a 24015 (4 págs.). Disponible en: https://www.boe.es/eli/es/o/2015/03/09/ssi445

Mokaya, J., Mellor, K. C., Murray, G. G. R., Kalizang’oma, A., Lekhuleni, C., Zar, H. J., Nicol, M. P., McGee, L., Bentley, S. D., Lo, S. W., & Dube, F. (2023). Genomic epidemiology of Streptococcus pneumoniae serotype 16F lineages. Microbial genomics, 9(11), 001123. doi:10.1099/mgen.0.001123

Instituto de Salud Carlos III. Centro Nacional de Epidemiología. Protocolo de vigilancia de la enfermedad neumocócica invasora; 2015. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/PROTOCOLOS/Protocolo%20de%20Vigilancia%20de%20Enfermedad%20Neumoc%C3%B3cica%20Invasora%20(ENI).pdf

Ministerio de Sanidad. Calendario común de vacunación a lo largo de toda la vida 2023. Consejo Interterritorial del Sistema Nacional de Salud. Calendario recomendado año 2023. Disponible en: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/calendario/Calendario_Todalavida_2023.htm

Ministerio de Sanidad. Vacunación específica en menores y adolescentes (<18 años) con condiciones de riesgo. Consejo Interterritorial del Sistema Nacional de Salud. Calendario recomendado año 2023. Disponible en: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/calendario/Calendario_Todalavida_2023.htm

Ministerio de Sanidad. Vacunación específica en menores y adolescentes (>18 años) con condiciones de riesgo. Consejo Interterritorial del Sistema Nacional de Salud. Calendario recomendado año 2023. Disponible en: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/calendario/Calendario_Todalavida_2023.htm

Ministerio de Sanidad. Vacunas bacterianas combinadas autorizadas en España. Agencia Española de Medicamentos y Productos Sanitarios. Disponible en: https://www.aemps.gob.es/medicamentos-de-uso-humano/medicamentos-biologicos/vacunas/comb_bacterianas/

European Centre for Disease Prevention and Control. TESSy metadata report. Disponible en: https://www.ecdc.europa.eu/en/publications-data/tessy-metadata-report

Finlandia. Pneumokokin esiintyvyys Suomessa 2023. Finnish institute for health and welfare. Disponible en: https://thl.fi/fi/web/infektiotaudit-ja-rokotukset/taudit-ja-torjunta/taudit-ja-taudinaiheuttajat-a-o/pneumokokki/pneumokokin-esiintyvyys-suomessa

Bélgica. National Reference Centre for invasive S. pneumoniae. Report National Reference Centre invasive Streptococcus pneumoniae 2023. Belgium. Disponible en: report_nrc_srpn_2023_final.pdf (sciensano.be)

Irlanda. Health Ptrotection Surveillance Centre. Infectious Disease Notifications in Ireland, 2019 – 2023. Disponible en: https://www.hpsc.ie/notifiablediseases/annualidstatistics/Annual_ID_Summary_Report_for_HPSC_Web_v9.0-2019-2023-15042024.pdf

Noruega. Pneumokokkinfeksjon - veileder for helsepersonell 2023 Norwegian Institute of Public Health. Disponible en: https://www.fhi.no/sm/smittevernveilederen/sykdommer-a-a/pneumokokkinfeksjon---veileder-for-/?term

Instituto de Salud Carlos III. Vigilancia centinela de Infección Respiratoria Aguda en Atención Primaria (IRAs) y en Hospitales (IRAG) en España: Gripe, COVID-19 y VRS Semana 52/2023 (del 25 al 31 de diciembre de 2023) Nº 163. 4 de enero de 2024. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/GRIPE/Informes%20semanales/Temporada_2023-24/Informe%20semanal_SiVIRA_522023.pdf

Soler-Soneira M, Granero-Melcón B, Sastre-García M, Bertrán-Pérez M, Amillategui-Dos-Santos R, Cano-Portero R. Enfermedad Neumocócica Invasiva en España en 2022. Boletín Epidemiológico Semanal. 2023;31(4):260-273. doi: 10.4321/s2173-92772023000400006

Inglaterra. UK Health Security Agency. Pneumococcal disease: cases caused by strains covered by PCV13. https://www.gov.uk/government/publications/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine

Inglaterra. UK Health Security Agency Pneumococcal disease infections caused by serotypes not in Prevenar 13 vaccine. Disponible en: https://www.gov.uk/government/publications/pneumococcal-disease-caused-by-strains-not-covered-by-prevenar-13-vaccine/pneumococcal-disease-infections-caused-by-serotypes-not-in-prevenar-13-vaccine

Instituto de Salud Carlos III. Vigilancia centinela de Infección Respiratoria Aguda en Atención Primaria (IRAs) y en Hospitales (IRAG) en España: Gripe, COVID-19 y VRS. Temporada 2022-202. Semana 40/2022 a semana 39/2023 https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/GRIPE/INFORMES%20ANUALES/Informe_ANUAL_SiVIRA_2022-23_08012024.pdf

Chiavenna, C., Presanis, A. M., Charlett, A., de Lusignan, S., Ladhani, S., Pebody, R. G., & De Angelis, D. (2019). Estimating age-stratified influenza-associated invasive pneumococcal disease in England: A time-series model based on population surveillance data. PLoS medicine, 16(6), e1002829. doi:10.1371/journal.pmed.1002829

Weinberger, D. M., Harboe, Z. B., Viboud, C., Krause, T. G., Miller, M., Mølbak, K., & Konradsen, H. B. (2014). Pneumococcal disease seasonality: incidence, severity and the role of influenza activity. The European respiratory journal, 43(3), 833–841. doi:10.1183/09031936.00056813

Cuypers L, Menten B, Sanchez GJ, et al. Rapid increase of vaccine serotype 4 (GPSC162) invasive pneumococcal disease in young adults since 2020 in Belgium. Abstract accepted as poster presentation for ISSPD 2024, South-Africa, March 2024.

Hernández, S., Moraga-Llop, F., Díaz, A., de Sevilla, M. F., Ciruela, P., Muñoz-Almagro, C., Codina, G., Campins, M., García-García, J. J., Esteva, C., Izquierdo, C., González-Peris, S., Martínez-Osorio, J., Uriona, S., Salleras, L., & Domínguez, Á. (2020). Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2-59 Months of Age, Spain. Emerging infectious diseases, 26(6), 1147–1155. doi:10.3201/eid2606.190951

Oligbu, G., Collins, S., Andrews, N., Sheppard, C. L., Fry, N. K., Slack, M. P. E., Borrow, R., & Ladhani, S. N. (2017). Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 65(7), 1191–1198. doi:10.1093/cid/cix418

Pérez-García, C., Sempere, J., de Miguel, S., Hita, S., Úbeda, A., Vidal, E. J., Llorente, J., Limia, A., de Miguel, A. G., Sanz, J. C., Martinón-Torres, F., Ardanuy, C., Domenech, M., & Yuste, J. (2024). Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023). The Journal of infection, 89(2), 106204. Advance online publication. doi:10.1016/j.jinf.2024.106204

Bertran, M., D’Aeth, J. C., Abdullahi, F., Eletu, S., Andrews, N. J., Ramsay, M. E., Litt, D. J., & Ladhani, S. N. (2024). Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. The Lancet. Infectious diseases, 24(5), 546–556. doi:10.1016/S1473-3099(23)00706-5

Published

2024-07-29

How to Cite

1.
Soler Soneira M, Del-Águila-Mejía J, Marina, Sastre-García M, Rocío, Cano Portero R. Invasive pneumococcal disease in Spain 2023. BES [Internet]. 2024 Jul. 29 [cited 2024 Nov. 21];32(2):74-93. Available from: //revista.isciii.es/index.php/bes/article/view/1381

Issue

Section

Estudios Epidemiológicos